Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969325 | 0.85 | KMT2A (0.41) | ELANEMAPTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL14979946 | 0.82 | POLB (0.51) | MAPTALDH1A1LMNACYP1A2HIF1A | |
| SCHEMBL14969694 | 0.78 | POLB (0.46) | MAPTALDH1A1LMNACYP1A2HIF1A | |
| SCHEMBL14967518 | 0.77 | MAPT (0.40) | MAPTALDH1A1LMNAHIF1AKDM4E | |
| SCHEMBL14967812 | 0.76 | MAPT (0.46) | PDE5AELANEMAPTL3MBTL1TDP1 | |
| SCHEMBL27914444 | 0.75 | PDE5A (0.56) | PDE5AELANEMAPTL3MBTL1TDP1 | |
| SCHEMBL9877583 | 0.73 | CYP1A2 (0.49) | MAPTLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL7560809 | 0.71 | LMNA (0.43) | MAPTL3MBTL1TDP1ALDH1A1LMNA | |
| SCHEMBL7562101 | 0.71 | ALDH1A1 (0.45) | MAPTL3MBTL1TDP1ALDH1A1LMNA | |
| SCHEMBL5583660 | 0.71 | KDM4E (0.41) | PDE5AELANEMAPTL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| EP-2618665-A1 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| WO-2013074386-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012040040-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040040-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, CTSC, GTF3C3 | PDE5A 2670/4885ELANE 376/4885MAPT 4369/4885 |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | PDE5A 2632/4885ELANE 435/4885MAPT 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.